Replacing traditional PEG-lipids in lipid nanoparticle formulations with zwitterionic polymer–lipid and brush polymer–lipid conjugates offers enhanced intracellular delivery and reduced immunogenicity, making them promising alternatives to PEGylated nanoparticles.